An independent laboratory found that IFNγ/IL-17-co-expressing CD4+ T cells are abundant in post-mortem MS lesions, and that lymphocytes obtained from relapsing MS patients have a propensity to expand into IFNγ/IL-17 co-producers [93]. This evidence concerns the gene IL17A and myeloid sarcoma.